Ribera, JordiGranada, IsabelMorgades, MireiaGonzález, TeresaCiudad, JuanaSuch, EsperanzaCalasanz, María JoséMercadal, SantiagoColl, RosaGonzález Campos, JoséTormo, MarGarcía Cadenas, IreneGil, CristinaCervera, MartaBarba, PereCosta, DolorsAyala, RosaBermúdez, AranchaOrfao, AlbertoRibera, Josep MariaPrograma Español de Tratamiento en Hematología (PETHEMA) Group Spanish Society Of Hematology (SEHH)2021-10-042021-10-042021-09-211365-2141https://hdl.handle.net/2445/180373The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent and adult patients with t(1;19)(q23;p13) enrolled in paediatric-inspired trials. The patients with TCF3-PBX1 showed similar MRD clearance and did not have different survival compared with other B-cell precursor ALL patients. However, patients with TCF3-PBX1 had a significantly higher cumulative incidence of relapse, especially among patients aged ≥35 years carrying additional cytogenetic alterations. These patients might benefit from additional/intensified therapy (e.g. immunotherapy in first complete remission with or without subsequent haematopoietic stem cell transplantation).6 p.application/pdfengcc by-nc-nd (c) Ribera, Jordi et al, 2021http://creativecommons.org/licenses/by-nc-nd/3.0/es/Pronòstic mèdicLeucèmiaCitogenètica humanaPrognosisLeukemiaHuman cytogeneticsinfo:eu-repo/semantics/article2021-10-01info:eu-repo/semantics/openAccess34549416